ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1261

Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA

(1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1578

Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1561

Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 0994

UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0916

UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway

(0916–0933) Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1217

Validation and clincial use of anti-MDA5 test – LIA versus ELISA

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1564

Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1125

Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout

(1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1479

Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1630

Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1103

Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1204

Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1131

Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance

(1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1562

Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1236

Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].